Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Narongsak Kiatikajornthada"'
Autor:
Metasebya Solomon, Gretchen Purcell Jackson, Yull E. Arriaga, Surasit Issarachai, Palita Lungchukiet, Rezzan Hekmat, Irene Dankwa-Mullan, Edward H. Shortliffe, Tanawat Jirakulaporn, Pattanawadee Wongrattananon, Nimit Taechakraichana, Wisanu Boonpakdee, Wimolrat Decha, Harit Suwanrusme, Suthida Suwanvecho, Vimla L. Patel, Anita M. Preininger, Narongsak Kiatikajornthada, Nittaya Thanakarn, Suwei Wang
Publikováno v:
Journal of the American Medical Informatics Association : JAMIA
Objective IBM(R) Watson for Oncology (WfO) is a clinical decision-support system (CDSS) that provides evidence-informed therapeutic options to cancer-treating clinicians. A panel of experienced oncologists compared CDSS treatment options to treatment
Autor:
Palita Lungchukiet, Nimit Taechakraichana, Jaime Esquivel, Rezzan Hekmat, Vimla L. Patel, Irene Dankwa-Mullan, Tanawat Jirakulaporn, Suthida Suwanvecho, Edward H. Shortliffe, Harit Suwanrusme, Wimolrat Decha, Suwei Wang, Pattanawadee Wongrattananon, Metasebya Solomon, Wisanu Boonpakdee, Yull E. Arriaga, Gretchen Purcell Jackson, Nittaya Thanakarn, Anita M. Preininger, Narongsak Kiatikajornthada
Publikováno v:
Journal of Clinical Oncology. 38:e14114-e14114
e14114 Background: Watson for Oncology (WfO) is an artificial intelligence-based clinical decision-support system which provides therapeutic options and associated scientific evidence to cancer-treating physicians. Oncologists at Bumrungrad Internati
Autor:
Palita Lungchukiet, Edward H. Shortliffe, Irene Dankwa-Mullan, Tanawat Jirakulaporn, Surasit Issarachai, Wimolrat Decha, Jaime Esquivel, Wisanu Boonpakdee, Vimla L. Patel, Pattanawadee Wongrattananon, Yull Edwin Arriaga, Harit Suwanrusme, Metasebya Solomon, Anita M. Preininger, Nimit Taechakraichana, Gretchen Purcell Jackson, Nittaya Thanakarn, Narongsak Kiatikajornthada, Suwei Wang, Suthida Suwanvecho
Publikováno v:
Journal of Global Oncology. 5:95-95
95 Background: Watson for Oncology (WFO) is an artificial intelligence (AI) based clinical decision-support tool trained by Memorial Sloan Kettering. This retrospective observational study of breast, lung, colon and rectal cancer examined the concord
Autor:
Tanawat Jirakulaporn, Suthida Suwanvecho, Edward H. Shortliffe, Palita Lungchukiet, Wimolrat Decha, Jaime Esquivel, Nimit Taechakraichana, Anita M. Preininger, Sarah Kefayati, Vimla L. Patel, Gretchen Purcell Jackson, Pattanawadee Wongrattananon, Irene Dankwa-Mullan, Nittaya Thanakarn, Narongsak Kiatikajornthada, Harit Suwanrusme, Surasit Issarachai, Wisanu Boonpakdee
Publikováno v:
Journal of Clinical Oncology. 37:6553-6553
6553 Background: Clinical decision-support systems (CDSS) such as Watson for Oncology (WFO) may reduce treatment variation in oncology, provided options offered by the system are at least as acceptable as expert, evidence-based options. Deviation fro
Autor:
Ching-Kun Wang, Theera Umsawasdi, Narongsak Kiatikajornthada, Wimolrat Decha, Alexandra Urman, Suthida Suwanvecho, Surasit Issarachai, Irene Dankwa-Mullan, Harit Suwanrusme
Publikováno v:
Journal of Clinical Oncology. 36:e18584-e18584
e18584Background: IBM Watson for Oncology (WFO) is a clinical decision support software that uses natural language processing (NLP) to assist providers to make expeditious treatment decisions. This...
Autor:
Narongsak Kiatikajornthada, Annette Hicks, Kyu Rhee, Alexandra Urman, Montinee Sangtian, Harit Suwanrusme, Andrew D. Norden, Irene Dankwa-Mullan, Suthida Suwanvecho
Publikováno v:
Journal of Clinical Oncology. 35:6589-6589
6589 Background: IBM Watson for Oncology (WFO) was trained by Memorial Sloan Kettering and is a cognitive computing system that uses natural language processing to ingest patient data in structured and unstructured formats. The system provides physic
Autor:
Narongsak Kiatikajornthada, Suebpong Tanasanvimon, Suthida Suwanvecho, Harit Suwanrusme, Suthinee Ithimakin, Nopadol Soparattanapaisarn, C. Akewanlop, Vichien Srimuninnimit, Napa Parinyanitikul, W. Chaiyarat, Virote Sriuranpong
Publikováno v:
Journal of Clinical Oncology. 29:e14633-e14633
e14633 Background: Currently, the only standard systemic treatment for advanced hepatocellular carcinoma (HCC) is sorafenib monotherapy. In searching for an improved regimen of systemic treatment, ...